Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › JNJ-42165279

JNJ-42165279

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of JNJ-42165279

3 trials tracked of JNJ-42165279.

3Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 3
  1. Phase 2 A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder Completed
  2. Phase 2 An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress Completed
  3. Phase 2 A Study to Investigate the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Participants With Autism Spectrum Disorder Completed

Showing the 3 most-cited and recently-updated of 3 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Adjunctive JNJ-42165279 fails to improve depression in SSRI/SNRI inadequate responders
Psychiatry RCT
Adjunctive JNJ-42165279 fails to improve depression in SSRI/SNRI inadequate responders Early trial finds new drug did not help depression in patients already on antidepressants
This phase 2a double-blind RCT tested adjunctive JNJ-42165279 25 mg daily versus placebo in 153 adults with major depressive disorder with a…
A small early study found a new drug did not improve depression symptoms for patients already taking standard antidepressants.
May 1, 2026